Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 11/20 | 0.74 |
| ▸ | NPY1R | P25929 | 1/20 | 0.63 |
| ▸ | NPY2R | P49146 | 1/20 | 0.63 |
| ▸ | NPY4R | P50391 | 1/20 | 0.63 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.63 |
| ▸ | GNRHR | P30968 | 1/20 | 0.60 |
| ▸ | GLP1R | P43220 | 6/20 | 0.59 |
| ▸ | MC4R | P32245 | 1/20 | 0.58 |
| ▸ | MC5R | P33032 | 1/20 | 0.58 |
| ▸ | MC3R | P41968 | 1/20 | 0.58 |
| ▸ | MC1R | Q01726 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29860804 | 1.00 | CXCR4 (0.74) | CXCR4NPY1RNPY2RNPY4RNPY5R | |
| SCHEMBL31650839 | 0.88 | CXCR4 (0.68) | CXCR4NPY1RNPY2RNPY4RNPY5R | |
| SCHEMBL29635486 | 0.87 | CXCR4 (0.73) | CXCR4NPY1RNPY2RNPY4RNPY5R | |
| SCHEMBL29437879 | 0.87 | CXCR4 (0.91) | CXCR4NPY1RNPY2RNPY4RNPY5R | |
| SCHEMBL29437878 | 0.87 | CXCR4 (0.91) | CXCR4NPY1RNPY2RNPY4RNPY5R | |
| SCHEMBL29421992 | 0.86 | CXCR4 (0.66) | CXCR4NPY1RNPY2RNPY4RNPY5R | |
| SCHEMBL29689766 | 0.86 | CXCR4 (0.66) | CXCR4NPY1RNPY2RNPY4RNPY5R | |
| SCHEMBL29358032 | 0.86 | CXCR4 (0.65) | CXCR4NPY1RNPY2RNPY4RNPY5R | |
| SCHEMBL31656488 | 0.85 | NPY1R (0.66) | CXCR4NPY1RNPY2RNPY4RNPY5R | |
| SCHEMBL30431758 | 0.84 | C5AR1 (0.69) | CXCR4GLP1RMC4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118127213-A | Molecular marker primer group based on magnolia officinalis and magnolia officinalis transcriptome sequencing and application | 绵阳师范学院 | 2024-06-04 | — | — | CN | claimed |
| WO-2026090160-A2 | CD4-TARGETED IL-15 MOLECULES AND METHODS OF USE | GILEAD SCIENCES, INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| US-20260109746-A1 | CD4-TARGETED IL-15 MOLECULES AND METHODS OF USE | GILEAD SCIENCES INC (US) | 2026-04-23 | — | — | US | disclosed |
| EP-4667499-A2 | INTERLEUKIN-2-FC FUSION PROTEINS AND METHODS OF USE | Gilead Sciences, Inc. (US) | 2025-12-24 | — | — | EP | disclosed |
| EP-4232463-B1 | INTERLEUKIN-2-FC FUSION PROTEINS AND METHODS OF USE | GILEAD SCIENCES INC (US) | 2025-09-03 | — | — | EP | disclosed |
| US-20240269235-A1 | INTERLEUKIN-2-Fc FUSION PROTEINS AND METHODS OF USE | GILEAD SCIENCES, INC. | 2024-08-15 | — | — | US | disclosed |
| CN-118127213-A | Molecular marker primer group based on magnolia officinalis and magnolia officinalis transcriptome sequencing and application | 绵阳师范学院 | 2024-06-04 | — | — | CN | disclosed |
| US-11896648-B2 | Interleukin-2 variant proteins fused to human IgG4 Fc and uses thereof | GILEAD SCIENCES, INC. (US) | 2024-02-13 | — | — | US | disclosed |
| EP-4232463-A2 | INTERLEUKIN-2-FC FUSION PROTEINS AND METHODS OF USE | GILEAD SCIENCES, INC. (US) | 2023-08-30 | — | — | EP | disclosed |
| CN-114277040-B | Construction method and application of efficient synthesis beta-carotene strain | 江南大学 | 2023-08-25 | — | — | CN | disclosed |
| CN-114410631-B | Construction method and application of high-efficiency synthesis of cembratriene-monoalcohol strain | 江南大学 | 2023-08-08 | — | — | CN | disclosed |
| EP-4204092-A1 | MULTI-SPECIFIC ANTIGEN BINDING MOLECULES TARGETING HIV AND METHODS OF USE | GILEAD SCIENCES, INC. (US) | 2023-07-05 | — | — | EP | disclosed |
| CN-109069577-B | D-peptide inhibitors of HIV entry and methods of use | 纳维根公司 | 2022-08-19 | — | — | CN | disclosed |
| CN-114410631-A | Construction method and application of efficient synthesis of cembratriene-alcohol strain | 江南大学 | 2022-04-29 | — | — | CN | disclosed |
| US-20220125884-A1 | INTERLEUKIN-2-Fc FUSION PROTEINS AND METHODS OF USE | GILEAD SCIENCES, INC. | 2022-04-28 | — | — | US | disclosed |
| WO-2022087149-A2 | INTERLEUKIN-2-FC FUSION PROTEINS AND METHODS OF USE | GILEAD SCIENCES, INC. (US) | 2022-04-28 | — | — | WO | disclosed |
| CN-114277040-A | Construction method and application of bacterial strain for efficiently synthesizing beta-carotene | 江南大学 | 2022-04-05 | — | — | CN | disclosed |
| WO-2022046644-A1 | MULTI-SPECIFIC ANTIGEN BINDING MOLECULES TARGETING HIV AND METHODS OF USE | GILEAD SCIENCES, INC. (US) | 2022-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260109746-A1 | CD4-TARGETED IL-15 MOLECULES AND METHODS OF USE | IL15, IL15RA, CD4 | CXCR4 968/4885NPY1R 469/4885NPY2R 709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.